Association study of a functional serotonin transporter gene polymorphism with schizophrenia, psychopathology and clozapine response

Schizophrenia Research

Volumn 44, Issue 3, 2000, Pages 177-181

  Tsai, Shih Jen ^a,b   Hong, Chen Jee ^a,b   Yu, Younger W Y ^c   Lin, Ching Hua ^c   Song, Hsiu Li ^a   Lai, Hao Che ^a   Yang, Kuan Hung ^c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c KAI SUAN PSYCHIATRIC HOSPITAL   (Taiwan)

Author keywords

Association study; Clozapine; Genotype; Psychopathology; Schizophrenia; Serotonin transporter

Indexed keywords

CLOZAPINE; SEROTONIN;

ADULT; ARTICLE; CLINICAL FEATURE; CORRELATION FUNCTION; DISEASE PREDISPOSITION; DNA POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PATHOGENESIS; PRIORITY JOURNAL; SCHIZOPHRENIA; SEROTONIN RELEASE; SEROTONINERGIC SYSTEM;

ADULT; ALLELES; ANTIPSYCHOTIC AGENTS; BRIEF PSYCHIATRIC RATING SCALE; CARRIER PROTEINS; CLOZAPINE; DNA PRIMERS; FEMALE; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0034283750     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(99)00170-X     Document Type: Article

References (21)

1. Austin M.C., Bradley C.C., Mann J.J., Blakely R.D. Expression of serotonin transporter messenger RNA in the human brain. J. Neurochem. 62:1994;2362-2367.
2. Bonnet-Brilhault F., Laurent C., Thibaut F., Campion D., Chavand O., Samolyk D., Martinez M., Petit M., Mallet J. Serotonin transporter gene polymorphism and schizophrenia: an association study. Biol. Psychiatry. 42:1997;634-636.
3. Buchanan R.W., Kirkpatrick B., Bryant N., Ball P., Breier A. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. Am. J. Psychiatry. 153:1996;1625-1627.
4. Chong S.A., Tan C.H., Lee H.S. Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: two case reports. J. Clin. Psychopharmacol. 17:1997;68-69.
5. Curtis V.A., Wright P., Reveley A., Kerwin R., Lucey J.V. Effect of clozapine on d-fenfluramine-evoked neuroendocrine responses in schizophrenia and its relationship to clinical improvement. Br. J. Psychiatry. 166:1995;642-646.
6. Dean B., Opeskin K., Pavey G., Naylor L., Hill C., Keks N., Copolov D.L. [3H]paroxetine binding is altered in the hippocampus but not the frontal cortex or caudate nucleus from subjects with schizophrenia. J. Neurochem. 64:1995;1197-1202.
7. Dean B., Hayes W., Opeskin K., Naylor L., Pavey G., Hill C., Keks N., Copolov D.L. Serotonin2 receptors and the serotonin transporter in the schizophrenic brain. Behav. Brain Res. 73:1996;169-175.
8. Heils A., Teufel A., Petri S., Stober G., Riederer P., Bengel D., Lesch K.P. Allelic variation of human serotonin transporter gene expression. J. Neurochem. 66:1996;2621-2624.
9. Hernandez I., Sokolov B.P. Abnormal expression of serotonin transporter mRNA in the frontal and temporal cortex of schizophrenics. Mol. Psychiatry. 2:1997;57-64.
10. Kahn R.S., Davidson M., Siever L., Gabriel S., Apter S., Davis K.L. Serotonin function and treatment response to clozapine in schizophrenic patients. Am. J. Psychiatry. 150:1993;1337-1342.
11. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry. 45:1988;789-796.
12. Laruelle M., Abi-Dargham A., Casanova M.F., Toti R., Weinberger D.R., Kleinman J.E. Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. Arch. Gen. Psychiatry. 50:1993;810-818.
13. Lin C.-H., Tsai S.-J., Yu Y.W.-Y., Song H.-L., Tu P.-C., Sim C.-B., Hsu C.-P., Yang K.-H., Hong C.-J. No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population. Neuroreport. 10:1999;57-60.
14. Malhotra A.K., Goldman D., Mazzanti C., Clifton A., Breier A., Pickar D. A functional serotonin transporter (5-HTT) polymorphism is associated with psychosis in neuroleptic-free schizophrenics. Mol. Psychiatry. 3:1998;328-332.
15. Meltzer H.Y. An overview of the mechanism of action of clozapine. J. Clin. Psychiatry. 55:(Suppl B):1994;47-52.
16. Mendes de Oliveira J.R., Otto P.A., Vallada H., Lauriano V., Elkis H., Lafer B., Vasquez L., Gentil V. Passos-Bueno M.R., Zatz M. Analysis of a novel functional polymorphism within the promoter region of the serotonin transporter gene (5-HTT) in Brazilian patients affected by bipolar disorder and schizophrenia. Am. J. Med. Genet. 81:1998;225-227.
17. Overall J.F., Gorham D.R. The Brief Psychiatric Rating Scale. Psychol. Rep. 10:1962;799-812.
18. Serretti A., Catalano M., Smeraldi E. Serotonin transporter gene is not associated with symptomatology of schizophrenia. Schizophr. Res. 35:1999;33-39.
19. Silver H., Shmugliakov N. Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study. J. Clin. Psychopharmacol. 18:1998;208-211.
20. Stober G., Jatzke S., Heils A., Jungkunz G., Fuchs E., Knapp M., Riederer P., Lesch K.P. Susceptibility for schizophrenia is not influenced by a functional insertion/deletion variant in the promoter of the serotonin transporter gene. Eur. Arch. Psychiatry Clin. Neurosci. 248:1998;82-86.
21. Yu Y.W.-Y., Tsai S.-J., Lin C.-H., Hsu C.-P., Yang K.-H., Hong C.-J. Serotonin-6 receptor variant (C267T) and clinical response to clozapine. Neuroreport. 10:1999;1231-1233.